You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 4
  • EP976 The impact of extent of cytoreductive surgery (CRS) on epithelial ovarian cancer (EOC), primary peritoneal carcinomatosis(PPC), and fallopian tube cancer (FTC) at the american university of beirut (AUBMC)

Article Text

Article menu
Download PDFPDF
ePoster
EP976 The impact of extent of cytoreductive surgery (CRS) on epithelial ovarian cancer (EOC), primary peritoneal carcinomatosis(PPC), and fallopian tube cancer (FTC) at the american university of beirut (AUBMC)
  1. M Seoud1,
  2. A El Housheimi1,
  3. I Jaafar2,
  4. K Hamed2,
  5. F Jamali3,
  6. R Abdallah1 and
  7. A Khalil1
  1. 1Obstetrics and Gynecology
  2. 2American Universtiy of Beirut Medical Center
  3. 3General Surgery, American Universtiy of Beirut Medical Center, Beirut, Lebanon

Abstract

Introduction/Background To study the impact of the extent of CRS [complete Debulking (CD), optimal Debulking (OD) ≤1 cm, or suboptimal Debulking (SOD) >1 cm residual disease] on progression free (PFS) and overall survival (OS) in advanced EOC who underwent primary debulking (PDS) or interval debulking surgery (IDS) between 1998–2018 at AUBMC.

Methodology A retrospective review of the impact of extent of CRS on PFS and OS.

Results of 300 patients with EOC, PPC and FTC, 220 were found to have advanced epithelial cancer (stage IIIB, IIIC and IV). 66.4% had CD, 29.7% OD and 2.6% SOD. Results are shown in tables 1 (Pic 1) and 2 and 3 (Pic 2). Median survival is expressed in months.

View this table:
Abstract EP976 Table 1

Extent of CRS and PFS and OS in stages IIIC and IV

View this table:
Abstract EP976 Table 2

CD in the primary versus interval setting in stage IIIC

View this table:
Abstract EP976 Table 3

PFS and OS of patients with CD in PDS versus IDS

Conclusion The extent of the cytoreductive surgery significantly prolonged PFS but not OS in stage IIIC but not IV. However this increase in PFS is only seen in the interval setting. Patients who undergo CD have similar PFS and OS regardless of the timing of CRS.

Disclosure Nothing to disclose.

https://doi.org/10.1136/ijgc-2019-ESGO.1022

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.